MCID: OVR012
MIFTS: 53

Ovarian Serous Cystadenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases

Aliases & Classifications for Ovarian Serous Cystadenocarcinoma

MalaCards integrated aliases for Ovarian Serous Cystadenocarcinoma:

Name: Ovarian Serous Cystadenocarcinoma 12 56 6 15 17 74
Serous Cystadenoma 12 17
Cystadenoma, Serous 74
Cystadenoma Serous 56

Classifications:



External Ids:

Disease Ontology 12 DOID:5746
NCIt 51 C7978

Summaries for Ovarian Serous Cystadenocarcinoma

Disease Ontology : 12 An ovary serous adenocarcinoma that has material basis in glandular epithelium, in which cystic accumulations of retained secretions are formed.

MalaCards based summary : Ovarian Serous Cystadenocarcinoma, also known as serous cystadenoma, is related to adenocarcinoma and endocrine gland cancer. An important gene associated with Ovarian Serous Cystadenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Innate Immune System and HIV Life Cycle. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include pancreas, ovary and thyroid, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Ovarian Serous Cystadenocarcinoma

Diseases related to Ovarian Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 169)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 30.8 BRAF ERBB2 HRAS PIK3CA TP53
2 endocrine gland cancer 30.4 ERBB2 HRAS TP53
3 fallopian tube carcinoma 30.4 ERBB2 PGR TP53
4 thyroid cancer 30.2 BRAF HRAS NRAS PIK3CA TP53
5 lung cancer susceptibility 3 30.0 BRAF ERBB2 HRAS NRAS PIK3CA TP53
6 serous cystadenocarcinoma 29.9 ERBB2 FBXW7 HRAS MUC16 PGR PIK3CA
7 cystadenocarcinoma 29.9 ERBB2 FBXW7 HRAS MUC16 PGR PIK3CA
8 endometrial cancer 29.4 BCL2 BRAF ERBB2 HRAS MUC16 PGR
9 ovarian cancer 28.8 BCL2 BRAF ERBB2 FSHR MUC16 PGR
10 pancreatic serous cystadenoma 12.7
11 serous or mucinous cystadenoma of childhood 11.3
12 cystadenoma 11.1
13 giant congenital nevus 10.5 HRAS NRAS
14 nevus of ota 10.5 BRAF TP53
15 adult hepatocellular carcinoma 10.5 PIK3CA TP53
16 rare adenocarcinoma of the breast 10.5 PIK3CA TP53
17 anal squamous cell carcinoma 10.4 FBXW7 PIK3CA TP53
18 malignant spiradenoma 10.4 PIK3CA TP53
19 apocrine adenoma 10.4 HRAS PIK3CA
20 gastric papillary adenocarcinoma 10.4 ERBB2 TP53
21 endometrium carcinoma in situ 10.4 PGR TP53
22 epithelial-myoepithelial carcinoma 10.4 FBXW7 HRAS TP53
23 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.4 PIK3CA PPP2R1A TP53
24 erdheim-chester disease 10.4 BRAF NRAS PIK3CA
25 breast squamous cell carcinoma 10.4 ERBB2 PIK3CA TP53
26 liver angiosarcoma 10.4 HRAS NRAS TP53
27 adenoma 10.4
28 prostate adenoid cystic carcinoma 10.4 HRAS LRRC56 PIK3CA
29 brain stem glioma 10.4 BRAF PIK3CA TP53
30 benign struma ovarii 10.4 HRAS NRAS
31 scirrhous adenocarcinoma 10.4 ERBB2 PGR
32 nevus, epidermal 10.4 HRAS NRAS PIK3CA
33 breast apocrine carcinoma 10.4 ERBB2 PGR
34 glassy cell carcinoma of the cervix 10.4 ERBB2 PGR
35 skin melanoma 10.4 BRAF NRAS TP53
36 adenosquamous lung carcinoma 10.4 ERBB2 HRAS PIK3CA
37 bladder squamous cell carcinoma 10.4 BRAF TP53
38 hyperplastic polyposis syndrome 10.4 BRAF TP53
39 intracystic papillary adenoma 10.3 ERBB2 PGR
40 colorectal adenocarcinoma 10.3 BRAF HRAS TP53
41 pulmonic stenosis 10.3 BRAF HRAS LRRC56
42 meningeal melanomatosis 10.3 B2M HRAS NRAS TP53
43 testicular germ cell tumor 10.3 BRAF HRAS TP53
44 breast metaplastic carcinoma 10.3 ERBB2 PGR
45 histiocytic sarcoma 10.3 BCL2 BRAF
46 intestinal disease 10.3 HRAS PIK3CA TP53
47 microglandular adenosis 10.3 ERBB2 PGR TP53
48 ovarian cystadenocarcinoma 10.3 HRAS UBE4A ZNF217
49 adrenocortical carcinoma, hereditary 10.3 BRAF NRAS PIK3CA TP53
50 breast benign neoplasm 10.3 ERBB2 PGR TP53

Graphical network of the top 20 diseases related to Ovarian Serous Cystadenocarcinoma:



Diseases related to Ovarian Serous Cystadenocarcinoma

Symptoms & Phenotypes for Ovarian Serous Cystadenocarcinoma

GenomeRNAi Phenotypes related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

27 (show all 23)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-10 10.29 USP2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 10.29 ZNF217
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 10.29 USP14
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.29 BCL2
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 10.29 BCL2
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.29 USP2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.29 ERBB2 ZNF217
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-155 10.29 ZNF217
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.29 BCL2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.29 ZNF217
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 10.29 BCL2
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 10.29 ZNF217
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 10.29 USP2
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.29 USP2
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.29 ZNF217
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 10.29 HRAS
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 10.29 BCL2
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.29 ERBB2
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.29 BCL2 HRAS USP14 USP2
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 10.29 BCL2 ZNF217
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 10.29 BCL2 ERBB2 HRAS ZNF217
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 10.29 HRAS USP14
23 Increased cell death HMECs cells GR00103-A-0 9.1 FBXW7 PGR PIK3CA PPP2R1A TP53 ZNF217

MGI Mouse Phenotypes related to Ovarian Serous Cystadenocarcinoma:

47 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.37 B2M BCL2 BRAF ERBB2 FBXW7 FSHR
2 behavior/neurological MP:0005386 10.33 BCL2 BRAF ERBB2 FSHR HRAS NRAS
3 cardiovascular system MP:0005385 10.31 B2M BCL2 BRAF ERBB2 FBXW7 FSHR
4 endocrine/exocrine gland MP:0005379 10.27 B2M BCL2 BRAF ERBB2 FBXW7 FSHR
5 homeostasis/metabolism MP:0005376 10.25 B2M BCL2 BRAF ERBB2 FBXW7 FSHR
6 growth/size/body region MP:0005378 10.21 B2M BCL2 BRAF ERBB2 FBXW7 FSHR
7 mortality/aging MP:0010768 10.17 B2M BCL2 BRAF ERBB2 FBXW7 FSHR
8 integument MP:0010771 10.15 B2M BCL2 BRAF ERBB2 FBXW7 FSHR
9 embryo MP:0005380 10.13 BCL2 BRAF ERBB2 FBXW7 NANOG NRAS
10 digestive/alimentary MP:0005381 10.1 B2M BCL2 BRAF ERBB2 FBXW7 HRAS
11 craniofacial MP:0005382 10.05 BCL2 BRAF ERBB2 FBXW7 HRAS NRAS
12 neoplasm MP:0002006 10.03 B2M BCL2 BRAF ERBB2 FBXW7 FSHR
13 no phenotypic analysis MP:0003012 9.7 HRAS NANOG NRAS PGR PIK3CA TP53
14 reproductive system MP:0005389 9.7 B2M BCL2 BRAF ERBB2 FSHR PATL2
15 skeleton MP:0005390 9.28 BRAF ERBB2 FSHR HRAS NRAS PGR

Drugs & Therapeutics for Ovarian Serous Cystadenocarcinoma

Drugs for Ovarian Serous Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 117)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
2
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
3
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
4
Bevacizumab Approved, Investigational Phase 3,Phase 1 216974-75-3
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
6
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Not Applicable 59-30-3 6037
8 Antimitotic Agents Phase 3,Phase 2,Phase 1
9 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
10 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
11 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
12 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
13 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
14 Angiogenesis Inhibitors Phase 3,Phase 1
15 Angiogenesis Modulating Agents Phase 3,Phase 1
16 Antineoplastic Agents, Immunological Phase 3,Phase 1
17 Immunoglobulins Phase 3,Phase 1
18 Endothelial Growth Factors Phase 3,Phase 1
19 Immunoglobulin G Phase 3,Phase 1
20 Mitogens Phase 3,Phase 1
21 Antibodies Phase 3,Phase 1
22 Antibodies, Monoclonal Phase 3,Phase 1
23 Antirheumatic Agents Phase 3,Phase 2,Phase 1
24 Peripheral Nervous System Agents Phase 3,Phase 1,Not Applicable
25 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
26 Alkylating Agents Phase 3,Phase 2,Phase 1
27 Analgesics Phase 3,Phase 1
28 Vitamin B Complex Phase 3,Not Applicable
29 Trace Elements Phase 3,Not Applicable
30 Folate Phase 3,Not Applicable
31 Vitamins Phase 3,Not Applicable
32 Micronutrients Phase 3,Not Applicable
33 Vitamin B9 Phase 3,Not Applicable
34 Nutrients Phase 3,Not Applicable
35
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 5284616 6436030
36
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
37
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
38
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
39
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
40
Belinostat Approved, Investigational Phase 2 866323-14-0
41
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
42
Topotecan Approved, Investigational Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
43
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
44
Docetaxel Approved, Investigational Phase 1, Phase 2,Phase 2 114977-28-5 148124
45
Metformin Approved Phase 2,Phase 1 657-24-9 14219 4091
46
Gemcitabine Approved Phase 2 95058-81-4 60750
47
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
48
Doxil Approved June 1999 Phase 2,Phase 1 31703
49
MK-1775 Investigational Phase 2 955365-80-7, 501-36-0 24856436 445154
50
Emodepside Investigational, Vet_approved Phase 2 155030-63-0

Interventional clinical trials:

(show top 50) (show all 66)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy Unknown status NCT02097446 Phase 3
2 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
3 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
4 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
5 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
6 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
7 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
8 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
9 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
10 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
11 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Unknown status NCT02283658 Phase 2 Everolimus;Letrozole
12 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
13 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
14 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
15 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
16 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
17 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
18 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer Completed NCT00008138 Phase 2 carboplatin;paclitaxel
19 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride
20 TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00022347 Phase 2 canfosfamide hydrochloride
21 Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2 carboplatin;docetaxel;erlotinib hydrochloride
22 Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers Completed NCT00002538 Phase 2
23 Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02122185 Phase 2 metformin hydrochloride;placebo;Chemotherapy
24 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
25 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer Terminated NCT00004221 Phase 2 Carboplatin;Cyclophosphamide;Paclitaxel;Topotecan Hydrochloride
26 Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Terminated NCT00331422 Phase 2 carboplatin;paclitaxel
27 Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer Terminated NCT00354601 Phase 2 capecitabine;docetaxel
28 Toremifene in Treating Patients With Ovarian Cancer Withdrawn NCT00003865 Phase 2 toremifene
29 EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01489371 Phase 1 Pegylated Liposomal Doxorubicin Hydrochloride
30 Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT01459380 Phase 1 Carboplatin;Pegylated Liposomal Doxorubicin Hydrochloride;Veliparib
31 TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Completed NCT01294293 Phase 1 TLR8 Agonist VTX-2337;Pegylated Liposomal Doxorubicin Hydrochloride;Paclitaxel
32 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
33 Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00814086 Phase 1 Paclitaxel;Cisplatin
34 Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer Completed NCT00357448 Phase 1
35 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
36 Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00079430 Phase 1 paclitaxel;carboplatin
37 Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer Completed NCT00002913 Phase 1 paclitaxel;cisplatin;topotecan hydrochloride
38 Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer Completed NCT00060359 Phase 1 Carboplatin;Paclitaxel Poliglumex
39 Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00006235 Phase 1 carboplatin;pegylated liposomal doxorubicin hydrochloride
40 Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer Completed NCT00002600 Phase 1 carboplatin;cyclophosphamide
41 Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003967 Phase 1 etoposide;topotecan hydrochloride
42 Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00652691 Phase 1 carboplatin;cyclophosphamide;topotecan hydrochloride
43 Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer Completed NCT00408590 Phase 1
44 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer Completed NCT00005026 Phase 1 carboplatin;paclitaxel;topotecan hydrochloride
45 Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors Completed NCT00066651 Phase 1
46 Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission Completed NCT00002977 Phase 1 melphalan;thiotepa
47 RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
48 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
49 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
50 Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003385 Phase 1 carboplatin;paclitaxel;pegylated liposomal doxorubicin hydrochloride

Search NIH Clinical Center for Ovarian Serous Cystadenocarcinoma

Genetic Tests for Ovarian Serous Cystadenocarcinoma

Anatomical Context for Ovarian Serous Cystadenocarcinoma

MalaCards organs/tissues related to Ovarian Serous Cystadenocarcinoma:

42
Pancreas, Ovary, Thyroid, Brain, Bone, Skin, Bone Marrow

Publications for Ovarian Serous Cystadenocarcinoma

Articles related to Ovarian Serous Cystadenocarcinoma:

(show top 50) (show all 256)
# Title Authors Year
1
The honeycomb pattern of pancreatic serous cystadenoma. ( 30288583 )
2019
2
Giant serous cystadenoma of the pancreas appearing sonographically as a remote pararenal mass. ( 30907433 )
2019
3
Giant Primary Retroperitoneal Serous Cystadenoma: A Rare Entity Mimicking Multiple Neoplastic and Nonneoplastic Processes. ( 31017452 )
2019
4
Macrocystic serous cystadenoma of the pancreas. ( 31023580 )
2019
5
A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma. ( 30097905 )
2018
6
Gastric metastasis of ovarian serous cystadenocarcinoma. ( 30233254 )
2018
7
Bilateral Breast and Axillary Lymph Nodes Metastases of an Ovarian Serous Cystadenocarcinoma. ( 30287996 )
2018
8
A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma. ( 30446011 )
2018
9
Two protein-coding genes act as a novel clinical signature to predict prognosis in patients with ovarian serous cystadenocarcinoma. ( 29456732 )
2018
10
An exceptional source of recurrent urinary tract infections in women: Primary retroperitoneal serous cystadenoma. ( 29458894 )
2018
11
Combined ovarian serous cystadenoma and thecoma. ( 29499871 )
2018
12
Middle segment pancreatectomy for a solid serous cystadenoma diagnosed by MRCP and review of the literature: A case report. ( 29725534 )
2018
13
Incidence and reasons of pancreatic resection in patients with asymptomatic serous cystadenoma. ( 29903633 )
2018
14
Atypical Solid Serous Cystadenoma of the Pancreas. ( 30454515 )
2018
15
Serous cystadenoma of pancreas: A clinicopathologic experience of 23 cases from a major tertiary care center. ( 30542522 )
2018
16
Expression of Yes-associated protein 1 and its clinical significance in ovarian serous cystadenocarcinoma. ( 28339095 )
2017
17
Discrimination of serous cystadenoma from mucinous cystadenoma in the pancreas with contrast-enhanced ultrasonography: a prospective study in 61 patients. ( 28280363 )
2017
18
Ovarian serous cystadenoma with ectopic adrenal tissue in a 65-year-old patient: A case report. ( 28285211 )
2017
19
Serous Cystadenoma of the Retroperitoneum. ( 28325663 )
2017
20
A Retroperitoneal Serous Cystadenoma of Müllerian Origin Masquerading as a Massive Renal Cyst. ( 28408339 )
2017
21
A Giant Primary Retroperitoneal Serous Cystadenoma: Case Report and Review of Retroperitoneal Cysts. ( 28825017 )
2017
22
Pancreatic solid serous cystadenoma treated by laparoscopy: Presentation of a new case report and review of the literature. ( 28965087 )
2017
23
Co-existence of Diffuse Serous Cystadenoma and Pancreatic Neuroendocrine Tumor. ( 29089709 )
2017
24
Elastography and Contrast-Enhanced Endoscopic Ultrasound Findings in a Pseudo-Solid Variant of a Pancreatic Serous Cystadenoma. ( 29255763 )
2017
25
Novel techniques for diagnosis of serous cystadenoma: fern pattern of vascularity confirmed by in vivo and ex vivo confocal laser endomicroscopy. ( 27449195 )
2017
26
The many faces of pancreatic serous cystadenoma: Radiologic and pathologic correlation. ( 27614585 )
2017
27
Serous Cystadenoma of the Pancreas Showing Uptake on 68Ga PSMA PET/CT. ( 27764044 )
2017
28
Serous Cystadenoma of the Pancreas: Potentials and Pitfalls of a Preoperative Cytopathologic Diagnosis. ( 27889754 )
2017
29
Single nucleotide polymorphisms in glutathione S-transferase P1 and M1 genes and overall survival of patients with ovarian serous cystadenocarcinoma treated with chemotherapy. ( 27073511 )
2016
30
Estimation of Prognostic Marker Genes by Public Microarray Data in Patients with Ovarian Serous Cystadenocarcinoma. ( 27189279 )
2016
31
A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma. ( 27478834 )
2016
32
DNA methylation-regulated microRNA pathways in ovarian serous cystadenocarcinoma: A meta-analysis. ( 27746113 )
2016
33
Serous cystadenoma of the pancreas with atypical clinical manifestations: A case report. ( 27073668 )
2016
34
Coexistent borderline serous cystadenoma with multifocal hydatidosis in a young female: lessons learnt. ( 27314257 )
2016
35
Incidental finding of a huge ovarian serous cystadenoma in an adolescent female with menorrhagia. ( 27489715 )
2016
36
Obstructive Jaundice as a Complication of Macrocystic Serous Cystadenoma of the Pancreas. ( 27550882 )
2016
37
Giant Serous Cystadenoma of the Pancreas (⩾10 cm): The Clinical Features and CT Findings. ( 27610132 )
2016
38
A Case of Serous Cystadenoma Communicating with a Stenotic Santorini's Duct and a Dilated Main Pancreatic Duct. ( 27981313 )
2016
39
Solid serous cystadenoma of the pancreas: a case report of 2 patients revealing vimentin, β-catenin, α-1 antitrypsin, and α-1 antichymotrypsin as new immunohistochemistry staining markers. ( 25816032 )
2015
40
Spleen preservation in a caudal pancreatic serous cystadenoma - case report. ( 25914751 )
2015
41
Laparoscopic fenestration of pancreatic serous cystadenoma: Minimally invasive approach for symptomatic benign disease. ( 26078583 )
2015
42
Macrocystic serous cystadenoma of the pancreas: Report of 4 cases. ( 26118606 )
2015
43
Serous Cystadenoma and Fibrothecoma: A Rare Combination in Collision Tumor of Ovary with Pseudo-Meigs Syndrome. ( 26148741 )
2015
44
Serous cystadenoma of pancreas: imaging diagnosis. ( 26591957 )
2015
45
Hepatoid carcinoma of the pancreas combined with serous cystadenoma: a case report and review of the literature. ( 26605284 )
2015
46
Analysis of VEGF/PlGF heterodimer level in pancreatic cyst fluid as a biomarker for serous cystadenoma. ( 31051713 )
2015
47
Tumor-to-tumor metastasis: report of two cases of renal cell carcinoma metastasizing to microcystic serous cystadenoma of the pancreas. ( 24873824 )
2015
48
Rapid shrinkage of a pancreatic serous cystadenoma with cystic degeneration: report of a case. ( 24990205 )
2015
49
A novel approach to the diagnosis of pancreatic serous cystadenoma: needle-based confocal laser endomicroscopy. ( 25325684 )
2015
50
Bilateral Sertoli cell adenoma in gonads, associated with serous cystadenoma. ( 25119177 )
2014

Variations for Ovarian Serous Cystadenocarcinoma

ClinVar genetic disease variations for Ovarian Serous Cystadenocarcinoma:

6 (show top 50) (show all 453)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
2 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
3 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
4 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
5 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
6 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
7 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
8 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
9 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
10 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh38 Chromosome 17, 7673806: 7673806
11 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
12 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
13 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
14 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
15 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
16 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
17 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
18 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
19 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
20 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
21 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
22 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
23 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
24 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
25 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
26 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
27 HRAS NM_176795.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
28 HRAS NM_176795.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
29 HRAS NM_005343.2(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
30 HRAS NM_005343.2(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
31 HRAS NM_005343.2(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
32 HRAS NM_005343.2(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
33 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
34 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
35 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
36 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
37 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
38 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
39 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
40 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
41 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
42 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
43 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
44 NRAS NM_002524.3(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
45 NRAS NM_002524.3(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
46 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
47 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 GRCh38 Chromosome 3, 179234296: 179234296
48 BRAF NM_004333.4(BRAF): c.1741A> C (p.Asn581His) single nucleotide variant Likely pathogenic rs180177040 GRCh37 Chromosome 7, 140453987: 140453987
49 BRAF NM_004333.4(BRAF): c.1741A> C (p.Asn581His) single nucleotide variant Likely pathogenic rs180177040 GRCh38 Chromosome 7, 140754187: 140754187
50 FBXW7 NM_033632.3(FBXW7): c.1513C> T (p.Arg505Cys) single nucleotide variant Likely pathogenic rs149680468 GRCh37 Chromosome 4, 153247289: 153247289

Expression for Ovarian Serous Cystadenocarcinoma

Search GEO for disease gene expression data for Ovarian Serous Cystadenocarcinoma.

Pathways for Ovarian Serous Cystadenocarcinoma

Pathways related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 B2M BCL2 BRAF ERBB2 FBXW7 HRAS
2
Show member pathways
13.77 B2M BRAF ERBB2 FBXW7 HRAS MUC16
3
Show member pathways
13.59 BCL2 BRAF ERBB2 HRAS NRAS PIK3CA
4
Show member pathways
13.49 B2M ERBB2 FBXW7 HRAS NRAS PIK3CA
5
Show member pathways
13.29 B2M BCL2 BRAF ERBB2 HRAS NANOG
6
Show member pathways
13.07 BCL2 HRAS NRAS PGR PIK3CA PPP2R1A
7
Show member pathways
13.02 BCL2 ERBB2 HRAS NRAS PIK3CA PPP2R1A
8
Show member pathways
13 B2M BCL2 HRAS NRAS PIK3CA TP53
9
Show member pathways
12.95 BCL2 BRAF ERBB2 HRAS NRAS PIK3CA
10
Show member pathways
12.9 BRAF ERBB2 HRAS NRAS PIK3CA
11
Show member pathways
12.88 BCL2 BRAF ERBB2 HRAS NRAS PIK3CA
12
Show member pathways
12.85 BCL2 HRAS NRAS PIK3CA TP53
13 12.84 BCL2 BRAF ERBB2 HRAS NRAS PIK3CA
14 12.8 BRAF ERBB2 HRAS NRAS TP53
15
Show member pathways
12.77 ERBB2 HRAS NRAS PIK3CA PPP2R1A TP53
16
Show member pathways
12.72 BCL2 BRAF HRAS NRAS PPP2R1A TP53
17
Show member pathways
12.68 BCL2 BRAF ERBB2 HRAS NRAS PIK3CA
18
Show member pathways
12.68 BCL2 BRAF ERBB2 HRAS NRAS PIK3CA
19
Show member pathways
12.62 BCL2 ERBB2 HRAS NRAS PIK3CA TP53
20
Show member pathways
12.59 BCL2 BRAF ERBB2 HRAS NRAS PGR
21
Show member pathways
12.58 BRAF ERBB2 HRAS NRAS PIK3CA TP53
22
Show member pathways
12.57 BRAF ERBB2 HRAS NRAS PIK3CA TP53
23
Show member pathways
12.54 BCL2 ERBB2 HRAS NRAS PIK3CA
24 12.52 BCL2 ERBB2 HRAS NRAS PIK3CA TP53
25
Show member pathways
12.5 BRAF ERBB2 HRAS NRAS PIK3CA TP53
26
Show member pathways
12.47 HRAS PIK3CA PPP2R1A TP53
27
Show member pathways
12.45 BCL2 BRAF HRAS NRAS
28
Show member pathways
12.44 BRAF ERBB2 HRAS NRAS PIK3CA
29
Show member pathways
12.42 BRAF HRAS NRAS PIK3CA
30
Show member pathways
12.42 BCL2 ERBB2 HRAS NRAS PIK3CA TP53
31 12.39 HRAS NRAS PIK3CA TP53
32
Show member pathways
12.39 BRAF PGR PIK3CA PPP2R1A
33
Show member pathways
12.37 BCL2 BRAF HRAS NRAS
34
Show member pathways
12.35 ERBB2 HRAS NRAS PIK3CA
35 12.33 HRAS NRAS PIK3CA TP53
36
Show member pathways
12.31 BRAF HRAS NRAS PIK3CA PPP2R1A
37
Show member pathways
12.29 BRAF HRAS NRAS TP53
38
Show member pathways
12.25 BCL2 HRAS NRAS PIK3CA
39 12.22 HRAS NRAS PIK3CA TP53
40
Show member pathways
12.2 BRAF HRAS NRAS TP53
41
Show member pathways
12.19 ERBB2 HRAS NRAS PIK3CA
42
Show member pathways
12.19 HRAS NRAS PIK3CA TP53
43
Show member pathways
12.19 BRAF HRAS NRAS PIK3CA TP53
44 12.15 HRAS NANOG NRAS PIK3CA
45
Show member pathways
12.14 BRAF HRAS NRAS PIK3CA
46
Show member pathways
12.13 BCL2 HRAS NRAS PIK3CA PPP2R1A
47 12.11 BCL2 HRAS NRAS PIK3CA
48
Show member pathways
12.09 BCL2 HRAS NRAS PPP2R1A
49
Show member pathways
12.09 BRAF ERBB2 PIK3CA TP53
50 12.09 BCL2 ERBB2 HRAS NRAS PIK3CA TP53

GO Terms for Ovarian Serous Cystadenocarcinoma

Biological processes related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.73 BRAF ERBB2 HRAS NRAS
2 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.65 BCL2 BRAF PIK3CA
3 Ras protein signal transduction GO:0007265 9.58 HRAS NRAS TP53
4 cell proliferation GO:0008283 9.56 BCL2 ERBB2 HRAS TP53
5 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.54 HRAS MUC16 NRAS
6 regulation of mitochondrial membrane permeability GO:0046902 9.46 BCL2 TP53
7 negative regulation of neuron apoptotic process GO:0043524 9.46 BCL2 BRAF HRAS PIK3CA
8 circadian behavior GO:0048512 9.32 TP53 USP2
9 cell aging GO:0007569 9.13 BCL2 HRAS TP53
10 positive regulation of ERK1 and ERK2 cascade GO:0070374 8.92 BRAF FBXW7 FSHR HRAS

Molecular functions related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.65 BCL2 BRAF ERBB2 PPP2R1A TP53
2 ubiquitin protein ligase binding GO:0031625 9.62 BCL2 FBXW7 TP53 USP2
3 protein binding GO:0005515 9.6 B2M BCL2 BRAF ERBB2 FBXW7 FSHR
4 identical protein binding GO:0042802 9.56 B2M BCL2 BRAF ERBB2 FBXW7 PGR
5 protein phosphatase binding GO:0019903 9.33 BCL2 ERBB2 TP53

Sources for Ovarian Serous Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....